Clinical Trial Update: Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

View source ↗

Summary

A Pfizer-sponsored study comparing palbociclib in combination with an aromatase inhibitor versus an aromatase inhibitor alone in Medicare patients with metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitor (class)
• Palbociclib (palbociclib)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Status: COMPLETED | Results posted: 2025-11-18